Patrick Terry, Scientia Advisors, presents at Genome-wide Partnering & Deal-making, May 30-31, Boston
Patrick Terry, Principle, Scientia Advisors LLC, will be giving a presentation entitled "Financing, Partnering, and Dealmaking in Stratified Medicine" at the Genome-wide Partnering & Deal-making Conference, May 30-31, 2012 in Boston, MA.
- Boston, MA-NH (1888PressRelease) April 28, 2012 - Beyond the global debt crisis and fiscal austerity measures, the economic pressure on the healthcare and medical innovation sectors has never been more intense. The challenges to execute in this environment are altering how basic translational science is conducted, how business to business deals are structured; which is resulting in alternative financing approaches, product development partnerships, derisking arrangements, and how shared-risk models are being devised.
The $41 billion dollar market for in vitro diagnostics is having greater influence on elucidating biology, defining disease sub-groups, predicting the likelihood of individual patient therapeutic benefit, various treatment options, or providing a rational tool to guide overall treatment decisions. This is the fastest-growing IVD segment with a 15--17% annual increase. Weather we call this area of activity stratified medicine, personalized medicine, or precision medicine; there is a seismic shift taking place on the role of advanced measurement science and technologies will have on how modern health care will be practiced, managed, and reimbursed.
Business conditions related to this area of innovation are changing rapidly, making sustainable deal structures between pharmaceutical and diagnostic companies even more complex than ever before. New stakeholder involvement and new demand requirements being made by regulators, health technology reviewers, health outcomes evaluators, market authorization groups, advocacy groups, payors, hospitals, pharmacy benefit managers, and other gate keepers are changing the rules of the partnering paradigm. These different stakeholders, their business models, and motivations can be very different from yours in making deals in the emerging age of managed health care markets.
Benefits of this talk include:
• Financing Companion Diagnostics
• Partnering Rx/Dx Co-development
• Biotechnology and Pharmaceutical Business Case
• New Business to Business Transactions
Patrick Terry is a social entrepreneur who has founded a series of philanthropic, research, and commercial organizations based on the life sciences, applied technology, and social-network theory. He co-founded Genomic Health (NASDAQ: GHDX), and is former Director at a pioneering personalized medicine company based in California. His perspective is forged from personal and family experiences with genetic disease and cancer, and extensive work in the patient advocacy community. He has published dozens of peer-reviewed scientific papers, articles, and book chapters in the fields of genetics, rare disease, and personalized medicine. Some of his recent activities include leadership positions on numerous trade associations, professional societies, corporate boards, and federal advisory bodies.
He has experience doing hands-on bench science, coordinating genetics research, conducting research on rare diseases, and managing a life sciences patent portfolio. He has received many honors and awards in the business and scientific communities in the U.S. and internationally. He has dedicated his career to helping people and advancing a patient-centered perspective in research, product development, and delivery of care. He is currently a Director at Sirius Genomics, TcLand Expression, BioLogos Foundation, and Grand Therapeutics.
Patrick also founded the following organizations: Personalized Medicine Coalition, 21st Century Medicine Coalition, PXE International, Genetic Alliance BioBank, International Genetic Alliance, European Personalized Medicine Diagnostic Association, and Grand Therapeutics.
The Genome-wide Partnering & Deal-making Conference is a partnering and business development conference for pharmaceutical, diagnostics, technology and healthcare companies. The conference will discuss investments and partnerships in the genomic field, companion diagnostics and partnering for personalized medicine, regulatory and reimbursement issues and the ethical, legal and social implications (ELSI) of human genome sequencing.
For more information, please visit Genome-wide Partnering & Dealmaking or www.gtcbio.com
Event Website: http://www.gtcbio.com/component/conference/?file=home&cn=Omics+Evolution+Summit&cid=81
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam